详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

11| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Institute of Laboratory Animal Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. [2]Ministry of Education and Training, Chengdu Second People's Hospital, Chengdu, China.

出处：

DOI：

ISSN：

关键词： Chimeric antigen receptor T-cell therapy (CAR–T) Tumor targeting therapy Influencing factor Solution strategies

摘要：

Chimeric antigen receptor T-cesll therapy (CAR-T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment. However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR-T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR-T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy. These factors have significantly impeded the widespread adoption and utilization of this therapeutic approach. In this paper, we comprehensively analyze recent preclinical and clinical reports on CAR-T therapy while summarizing crucial factors influencing its efficacy. Furthermore, we aim to identify existing solution strategies and explore their current research status. Through this review article, our objective is to broaden perspectives for further exploration into CAR-T therapy strategies and their clinical applications.© 2024 The Authors.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2023]版：

Q3 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY

影响因子： 2 最新[2023版] 3.1 最新五年平均 2 出版当年[2023版] 0 出版当年五年平均 2 出版前一年[2023版]

第一作者：

第一作者机构： [1]Department of Institute of Laboratory Animal Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy [2]Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy [3]The Role of Mesenchymal Stem Cells in Cancer Immunotherapy [4]Targeting FGFRs for tumor therapy: current status and novel strategies [5]靶向血管的抗肿瘤治疗 [6]己糖激酶Ⅱ与肿瘤增殖及靶向治疗 [7]Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy [8]VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment [9]Moral courage and its influencing factor among oncology specialist nurses: A multi-centre cross-sectional study [10]Moral courage and its influencing factor among oncology specialist nurses: A multi-centre cross-sectional study